tisagenlecleucel Kymriah
Selected indexed studies
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. (N Engl J Med, 2018) [PMID:29385370]
- Kymriah® (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy. (Hum Vaccin Immunother, 2023) [PMID:37185251]
- Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. (Nat Med, 2022) [PMID:34921238]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Current Progress in CAR-T Cell Therapy for Solid Tumors. (2019) pubmed
- Kymriah® (tisagenlecleucel) - An overview of the clinical development journey of the first approved CAR-T therapy. (2023) pubmed
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. (2018) pubmed
- Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. (2022) pubmed
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. (2019) pubmed
- Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. (2022) pubmed
- Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. (2021) pubmed
- Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. (2023) pubmed
- PMID:38320065 (2023) pubmed
- PMID:38295211 (2023) pubmed